CPRX
Catalyst·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CPRX
Catalyst Pharmaceuticals, Inc.
A commercial-stage biopharmaceutical company that develops prescription drugs for neuromuscular and neurological diseases and disorders
355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134
--
Catalyst Pharmaceuticals, Inc., was incorporated in Delaware in July 2006. The Company is a commercial-stage, patient-centric biopharmaceutical company focused on the licensing, development and commercialization of new high-quality medicines for patients with rare and difficult-to-treat diseases. The company uses a concerted and diligent effort to find therapies that can improve the lives of those with rare or difficult-to-treat diseases.
Earnings Call
Q1/2025
Estimate EPS0.53
Actual EPS0.68
Estimate Revenue131.13M
Actual Revenue141.42M
Catalyst Pharmaceuticals' Q1 2025: Unpacking Contradictions in FIRDAPSE Growth and Market Dynamics
May 19,2025 01:39
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CPRX has released its 2025 Q3 earnings. EPS was reported at 0.68, versus the expected 0.54, beating expectations. The chart below visualizes how CPRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CPRX has released its 2025 Q3 earnings report, with revenue of 148.39M, reflecting a YoY change of 15.31%, and net profit of 52.78M, showing a YoY change of 20.28%. The Sankey diagram below clearly presents CPRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
